Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delgocitinib in Frontal Fibrosing Alopecia
NCT07671157Phase 2Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of delgocitinib in frontal fibrosing alopecia (FFA). Primary endpoint: Hairline measurements at 24 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
delgocitinib
03
Conditions
frontal fibrosing alopecia (FFA)
Beyond the preview
Go deeper on NCT07671157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07671157.